TTM Technologies, Inc. to Acquire Anaren, Inc.

Dec 04, 2017 01:00 am UTC| Business

Broadens Product Portfolio, Adding Highly Engineered RF Components and Subsystems for Aerospace Defense and Communications End Markets Transaction Expected to be Accretive COSTA MESA, Calif., Dec. 03, 2017 -- TTM...

Roquan Smith of Georgia Wins 33rd Collegiate Butkus Award®

Dec 04, 2017 00:46 am UTC| Business

ATHENS, Ga., Dec. 03, 2017 -- The 33rd annual collegiate Butkus Award® honoring the nation’s best collegiate linebacker was presented today to Roquan Smith, a junior at the University of Georgia. ...

Medigus Announces Distribution Agreement with Micro-Tech Europe for the MUSE™ System in Germany

Dec 04, 2017 00:09 am UTC| Business

OMER, Israel, Dec. 03, 2017 -- OMER, Israel - December 3, 2017 – Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization...

SNOMED International Maintains its Commitment to the Use of SNOMED CT through Broadened Implementation Approaches

Dec 03, 2017 23:00 pm UTC| Business

London, U.K., Dec. 03, 2017 -- SNOMED International’s continuing commitment to champion and shepherd global health information standards is a responsibility we faithfully serve in partnership with our 30 Members, 1600+...

Telix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc.

Dec 03, 2017 22:00 pm UTC| Business

MELBOURNE, Australia and INDIANAPOLIS, Dec. 04, 2017 -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic...

Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)

Dec 03, 2017 17:01 pm UTC| Business

- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – ...

Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

Dec 03, 2017 15:00 pm UTC| Business

- Phase 1 Clinical Trials of TAK-935/OV935 Demonstrated a Strong Safety Profile and Well Characterized Pharmacokinetic Profile, Supporting Further Clinical Advancement - - Results Support Plasma 24S-hydroxycholesterol...